Catalysts for National Cancer Institute US
10 tracked
Apr 30, 2026
phase 2 completion
National Cancer Institute US — ipilimumab (Phase II Trial Completion)
ipilimumab
→
Apr 30, 2026
phase 1 2 initiation
National Cancer Institute US — PEP-CMV (Phase I/II Trial Initiation)
PEP-CMV
→
Apr 30, 2026
phase 1 completion
National Cancer Institute US — emavusertib hydrochloride (Phase I Trial Completion)
emavusertib hydrochloride
→
Apr 30, 2026
phase 1 completion
National Cancer Institute US — tuvusertib (Phase I Trial Completion)
tuvusertib
→
Apr 29, 2026
phase 2 initiation
National Cancer Institute US — (daratumumab + hyaluronidase (human recombinant)) (Phase II Trial Initiation)
(daratumumab + hyaluronidase (human recombinant))
→
Apr 28, 2026
phase 1 completion
National Cancer Institute US — undisclosed chemotherapy (Phase I Trial Completion)
undisclosed chemotherapy
→
Apr 27, 2026
phase 2 initiation
National Cancer Institute US — cyclophosphamide (Phase II Trial Initiation)
cyclophosphamide
→
Apr 27, 2026
phase 2 initiation
National Cancer Institute US — busulfan (Phase II Trial Initiation)
busulfan
→
Apr 27, 2026
phase 1 2 initiation
National Cancer Institute US — sacituzumab govitecan (Phase I/II Trial Initiation)
sacituzumab govitecan
→
Apr 27, 2026
phase 1 initiation
National Cancer Institute US — Autologous B7-H3 CAR T (Phase I Trial Initiation)
Autologous B7-H3 CAR T
→